XiaoLing Fang

Find an error

Name: 方晓玲; XiaoLing Fang
Organization: Fudan University
Department: Key Laboratory of Smart Drug Delivery, Ministry of Education & Department of Pharmaceutics, School of Pharmacy, Center for Nano Drug/Gene Delivery and Tissue Engineering
Title: Professor

TOPICS

Co-reporter:Xinyi Jiang;Hongliang Xin;Jijin Gu;Fengyi Du;Chunlai Feng;Yike Xie
Journal of Pharmaceutical Sciences 2014 Volume 103( Issue 5) pp:
Publication Date(Web):
DOI:10.1002/jps.23928

The poor selectivity of chemotherapeutics for cancer treatment may lead to dose-limiting side effects that compromise clinical outcomes. To solve the problem, surface-functionalized polymer nanoparticles are regarded as promising tumor-targeting delivery system. On the basis of glucose transporter (GLUT) overexpression on cancer cells, d-glucosamine-conjugated and paclitaxel-loaded poly(ethylene glycol)-co-poly(trimethylene carbonate) copolymer nanoparticles (DGlu-NP/PTX) were developed as potential tumor-targeting drug delivery system in this study. Because of the high affinity between d-glucosamine and GLUT, DGlu-NP/PTX could target to tumor tissue through GLUT-mediated endocytosis to improve the selectivity of PTX. DGlu-NP/PTX was prepared by emulsion/solvent evaporation technique and characterized in terms of morphology, size, and zeta potential. In vitro evaluation of two-dimensional cells and three-dimensional tumor spheroids revealed that DGlu-NP/PTX was more potent than those of plain nanoparticles (NP/PTX) and Taxol. In vivo multispectral fluorescent imaging indicated that DGlu-NP had higher specificity and efficiency on subcutaneous xenografts tumor of mouse. Furthermore, DGlu-NP/PTX showed the greatest tumor growth inhibitory effect on in vivo subcutaneous xenografts model with no evident toxicity. Therefore, these results demonstrated that DGlu-NP/PTX could be used as potential vehicle for cancer treatment. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:1487–1496, 2014

Co-reporter:Qiuyue Ren;Chunli Deng;Lin Meng;Yanzuo Chen;Liangcen Chen;Xianyi Sha
Journal of Pharmaceutical Sciences 2014 Volume 103( Issue 6) pp:1680-1691
Publication Date(Web):
DOI:10.1002/jps.23958

In this study, the effect of the saturated fatty acid (FA) chain length in the oil phase on the behavior of Ibuprofen (IBU)-loaded transdermal microemulsion (ME) was evaluated in vitro, ex vivo, and in vivo. Three oils classified as long (LFA), medium (MFA), and short (SFA) chain length oils, Cremophor RH40 (surfactant) and Transcutol P (cosurfactant) were selected after experimental optimization. The physicochemical properties of ME were characterized, including IBU solubility in excipients, pseudo-ternary phase diagram construction, particle size, zeta potential, viscosity, and stability. Permeation flux and residual amount of IBU ex vivo using Franz cell system occurred in the following order: MFA-based ME > LFA-based ME > SFA-based ME, which correlated well with the results of confocal scanning laser microscopy study and the in vivo retention study. The results of in vitro cytotoxicity study and skin irritation tests measured by differential scanning calorimetry were ranked in the following order: LFA-based ME > MFA-based ME > SFA-based ME. Moreover, MFA-based ME has the highest analgesic activity among all the treatment groups. MFA was found to be an optimal oil phase with appropriate FA chain length for IBU-loaded transdermal ME, which exhibited excellent physicochemical properties, low toxicity, and good permeability profile. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci

Co-reporter:Xinyi Jiang, Hongliang Xin, Qiuyue Ren, Jijin Gu, Lingjun Zhu, Fengyi Du, Chunlai Feng, Yike Xie, Xianyi Sha, Xiaoling Fang
Biomaterials 2014 35(1) pp: 518-529
Publication Date(Web):
DOI:10.1016/j.biomaterials.2013.09.094
Co-reporter:Xinyi Jiang, Xianyi Sha, Hongliang Xin, Ximing Xu, Jijin Gu, Weiyi Xia, Shuo Chen, Yike Xie, Liangcen Chen, Yanzuo Chen, Xiaoling Fang
Biomaterials 2013 34(12) pp: 2969-2979
Publication Date(Web):
DOI:10.1016/j.biomaterials.2012.12.049
Co-reporter:Xinyi Jiang, Hongliang Xin, Jijin Gu, Ximing Xu, Weiyi Xia, Shuo Chen, Yike Xie, Liangcen Chen, Yanzuo Chen, Xianyi Sha, Xiaoling Fang
Biomaterials 2013 34(6) pp: 1739-1746
Publication Date(Web):
DOI:10.1016/j.biomaterials.2012.11.016
Co-reporter:Hongliang Xin, Xianyi Sha, Xinyi Jiang, Liangcen Chen, Kitki Law, Jijin Gu, Yanzuo Chen, Xiao Wang, Xiaoling Fang
Biomaterials 2012 33(5) pp: 1673-1681
Publication Date(Web):
DOI:10.1016/j.biomaterials.2011.11.018
Co-reporter:Hongliang Xin, Xianyi Sha, Xinyi Jiang, Wei Zhang, Liangcen Chen, Xiaoling Fang
Biomaterials 2012 33(32) pp: 8167-8176
Publication Date(Web):
DOI:10.1016/j.biomaterials.2012.07.046
Co-reporter:Yongzhong Wang, Junguo Hao, Yajuan Li, Zhiwen Zhang, Xianyi Sha, Limei Han, Xiaoling Fang
Biomaterials 2012 33(18) pp: 4741-4751
Publication Date(Web):
DOI:10.1016/j.biomaterials.2012.03.013
Co-reporter:Wei Zhang, Yuan Shi, Yanzuo Chen, Junguo Hao, Xianyi Sha, Xiaoling Fang
Biomaterials 2011 Volume 32(Issue 25) pp:5934-5944
Publication Date(Web):September 2011
DOI:10.1016/j.biomaterials.2011.04.075
Co-reporter:Hongliang Xin, Xinyi Jiang, Jijin Gu, Xianyi Sha, Liangcen Chen, Kitki Law, Yanzuo Chen, Xiao Wang, Ye Jiang, Xiaoling Fang
Biomaterials 2011 32(18) pp: 4293-4305
Publication Date(Web):
DOI:10.1016/j.biomaterials.2011.02.044
Co-reporter:Wei Zhang, Yuan Shi, Yanzuo Chen, Jiang Ye, Xianyi Sha, Xiaoling Fang
Biomaterials 2011 32(11) pp: 2894-2906
Publication Date(Web):
DOI:10.1016/j.biomaterials.2010.12.039
Co-reporter:Xinyi Jiang, Xianyi Sha, Hongliang Xin, Liangcen Chen, Xihui Gao, Xiao Wang, Kitki Law, Jijin Gu, Yanzuo Chen, Ye Jiang, Xiaoqing Ren, Qiuyue Ren, Xiaoling Fang
Biomaterials 2011 32(35) pp: 9457-9469
Publication Date(Web):
DOI:10.1016/j.biomaterials.2011.08.055
Co-reporter:Xinyi Jiang, Hongliang Xin, Jijin Gu, Fengyi Du, ... Xiaoling Fang
Journal of Pharmaceutical Sciences (May 2014) Volume 103(Issue 5) pp:1487-1496
Publication Date(Web):1 May 2014
DOI:10.1002/jps.23928
The poor selectivity of chemotherapeutics for cancer treatment may lead to dose-limiting side effects that compromise clinical outcomes. To solve the problem, surface-functionalized polymer nanoparticles are regarded as promising tumor-targeting delivery system. On the basis of glucose transporter (GLUT) overexpression on cancer cells, d-glucosamine-conjugated and paclitaxel-loaded poly(ethylene glycol)-co-poly(trimethylene carbonate) copolymer nanoparticles (DGlu-NP/PTX) were developed as potential tumor-targeting drug delivery system in this study. Because of the high affinity between d-glucosamine and GLUT, DGlu-NP/PTX could target to tumor tissue through GLUT-mediated endocytosis to improve the selectivity of PTX. DGlu-NP/PTX was prepared by emulsion/solvent evaporation technique and characterized in terms of morphology, size, and zeta potential. In vitro evaluation of two-dimensional cells and three-dimensional tumor spheroids revealed that DGlu-NP/PTX was more potent than those of plain nanoparticles (NP/PTX) and Taxol. In vivo multispectral fluorescent imaging indicated that DGlu-NP had higher specificity and efficiency on subcutaneous xenografts tumor of mouse. Furthermore, DGlu-NP/PTX showed the greatest tumor growth inhibitory effect on in vivo subcutaneous xenografts model with no evident toxicity. Therefore, these results demonstrated that DGlu-NP/PTX could be used as potential vehicle for cancer treatment. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Association.
Co-reporter:Qiuyue Ren, Chunu Deng, Un Meng, Yanzuo Chen, ... Xiaoung Fang
Journal of Pharmaceutical Sciences (June 2014) Volume 103(Issue 6) pp:1680-1691
Publication Date(Web):1 June 2014
DOI:10.1002/jps.23958
In this study, the effect of the saturated fatty acid (FA) chain length in the oil phase on the behavior of Ibuprofen (IBU)-loaded transdermal microemulsion (ME) was evaluated in vitro, ex vivo, and in vivo. Three oils classified as long (LFA), medium (MFA), and short (SFA) chain length oils, Cremophor RH40 (surfactant) and Transcutol P (cosurfactant) were selected after experimental optimization. The physicochemical properties of ME were characterized, including IBU solubility in excipients, pseudo-ternary phase diagram construction, particle size, zeta potential, viscosity, and stability. Permeation flux and residual amount of IBU ex vivo using Franz cell system occurred in the following order: MFA-based ME > LFA-based ME > SFA-based ME, which correlated well with the results of confocal scanning laser microscopy study and the in vivo retention study. The results of in vitro cytotoxicity study and skin irritation tests measured by differential scanning calorimetry were ranked in the following order: LFA-based ME > MFA-based ME > SFA-based ME. Moreover, MFA-based ME has the highest analgesic activity among all the treatment groups. MFA was found to be an optimal oil phase with appropriate FA chain length for IBU-loaded transdermal ME, which exhibited excellent physicochemical properties, low toxicity, and good permeability profile. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:1680-1691, 2014
Co-reporter:Li-Jun Zhang, Bin Xing, Jiang Wu, Bai Xu, Xiao-Ling Fang
Pulmonary Pharmacology & Therapeutics (February 2008) Volume 21(Issue 1) pp:239-246
Publication Date(Web):1 February 2008
DOI:10.1016/j.pupt.2007.04.002
This study was designed to investigate in vitro release, in vivo tissue distribution and the damage to the lungs of 9-nitrocamptothecin (9-NC) liposomes. In vitro release of 9-NC from liposomes was carried out in phosphate buffer saline solution (PBS) pH 7.4. The tissue distribution of 9-NC liposomes and 9-NC solution was determined after pulmonary delivery to mice. The tissue distribution of 9-NC liposomes after intravenous administration was also studied. The changes of pulmonary edema index and histology of lungs in rats were investigated to evaluate the severity of the damage after pulmonary delivery. The results showed that 9-NC was continuously released from liposomes in PBS pH 7.4 for 24 h at 37 °C. After pulmonary delivery, the mean residence time (MRT) of 9-NC liposomes in the lungs was 3.4 times as long as that of 9-NC solution and the total AUC0−t of all tissues in mice of the liposomes was 2.2-fold higher than that of the solution, indicating that the liposomes had sustained-release characteristics. Following intravenous administration and pulmonary delivery, the targeting efficiency (Te) to the lung of 9-NC liposomes was 0.14 and 2.02, respectively, which showed that intratracheal instillation can deliver the drug mainly to the lung and decrease the accumulation of the drug in other tissues at different concentrations. The pulmonary edema index and the histological changes of the lungs in 9-NC liposome group were significantly different from those in 9-NC solution group. The lung damage by liposomes was less severe than that by solution. Pulmonary delivery of 9-NC liposomes could directly deliver the drug to the lung and make the drug accumulate in the lung with sustained-release characteristics, changing the disposition behavior in vivo, decreasing the toxic and side effects on other tissues and reduce the severity of damage to lungs following intratracheal instillation.
Poly[oxy-1,4-butanediyloxy(1-oxo-1,3-propanediyl)[(5-hydroxypentyl)imi no](3-oxo-1,3-propanediyl)]
Cyclohexanecarboxylic acid, 4-[(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)methyl]-, 2,5-dioxo-3-sulfo-1-pyrrolidinyl ester
Vitamin E
Dodecanoic acid, monoester with 1,2,3-propanetriol
Poly[imino[(1S)-1-(1H-imidazol-4-ylmethyl)-2-oxo-1,2-ethanediyl]]
L-Histidine,homopolymer
(S)-2-(4-(((2,4-Diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)pentanedioic acid
1,3-dioxan-2-one
2,5,7,8-Tetramethyl-2-(4,8,12-trimethyltridecyl)chroman-6-ol